A Phase 1/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 410 Alone and in Combination with other agents in Participants with KRAS Altered Advanced or Metastatic Solid Tumors
Clinical Trial Grant
Awarded By
Amgen, Inc.
Start Date
September 8, 2025
End Date
September 18, 2030
Awarded By
Amgen, Inc.
Start Date
September 8, 2025
End Date
September 18, 2030